Related Experiment Video
Updated: Apr 6, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Novel Therapeutics for Pancreatic Adenocarcinoma
Maeve A Lowery1, Eileen M O'Reilly1
1Gastrointestinal Oncology Service, Department of Medicine, Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 300 East 66th Street, New York, NY 10065, USA.
Abstract:
The last decade has seen significant developments in the use of combination systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC), with median survival approaching 1 year for select patients treated with FOLFIRINOX in the metastatic setting. However, it is sobering that these developments have been achieved with the use of traditional cytotoxics rather than from successes in the more modern fields of molecularly targeted therapies or immunotherapy. This article highlights several promising therapeutic approaches to PDAC currently under clinical evaluation, including immune therapies, molecularly targeted therapies, strategies for stromal depletion, and targeted therapy for genetically selected patients.
Insights
Advanced pancreatic cancer treatment has improved with combination therapies like FOLFIRINOX, but new approaches like immunotherapy and targeted therapies are under investigation for better outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Medical Research
Background:
- Advanced pancreatic ductal adenocarcinoma (PDAC) survival has improved with combination chemotherapy, reaching nearly one year with FOLFIRINOX.
- Current progress relies on traditional cytotoxics, with limited success from modern targeted therapies or immunotherapies in PDAC.
Purpose of the Study:
- To review promising novel therapeutic strategies for advanced pancreatic ductal adenocarcinoma.
- To highlight ongoing clinical evaluations of immune therapies, molecularly targeted agents, stromal depletion, and precision medicine for PDAC.
Main Methods:
- Literature review of recent clinical trials and research in advanced pancreatic cancer.
- Analysis of emerging therapeutic modalities including immunotherapy, targeted therapy, and stromal modulation.
- Focus on strategies for genetically selected patient populations.
Main Results:
- FOLFIRINOX has extended median survival in metastatic PDAC to approximately one year.
- Despite advances, novel approaches like targeted therapies and immunotherapy have yet to demonstrate significant breakthroughs in PDAC.
- Several promising strategies are in clinical evaluation for PDAC.
Conclusions:
- While traditional chemotherapy has improved survival, novel therapeutic avenues are crucial for advancing PDAC treatment.
- Immune therapies, molecularly targeted agents, stromal depletion, and precision medicine represent promising future directions for PDAC.
- Continued clinical evaluation is essential to realize the potential of these new therapeutic strategies for advanced pancreatic cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy